What is Aimovig, and why is it linked to vestibular migraine?
Aimovig is the brand name for erenumab, a preventive migraine medicine that targets the CGRP pathway. Vestibular migraine is a migraine subtype where dizziness, vertigo, and balance symptoms are prominent, often alongside or related to typical migraine features. Because vestibular migraine is considered part of the migraine spectrum, preventive CGRP-blocking approaches like erenumab are sometimes used when dizziness episodes are thought to be migraine-driven.
How is Aimovig used for vestibular migraine (dose and timing)?
Aimovig is typically given as a once-monthly subcutaneous injection. The dosing schedule and whether it helps vestibular symptoms usually get assessed over a few treatment cycles, since preventive migraine therapies are evaluated after several months rather than after a single dose.
What results do people typically look for with vestibular migraine?
People using preventive migraine treatments for vestibular migraine generally monitor changes in:
- frequency of vertigo/dizziness attacks
- severity of those episodes
- ability to function during attacks (work, walking, driving)
- need for “rescue” medicines during flare-ups
How does this compare with other preventive options for vestibular migraine?
Vestibular migraine prevention often includes a mix of migraine-directed strategies, such as:
- other migraine preventive medicines (for example, beta-blockers, certain antidepressants, and antiseizure preventives)
- CGRP pathway drugs (including other monoclonal antibodies or related agents)
- lifestyle triggers management and vestibular rehabilitation in some patients
Aimovig’s distinguishing feature is that it directly blocks the CGRP receptor, which differs from preventive drugs that target other signaling pathways.
Who might be a candidate for Aimovig in vestibular migraine?
Clinicians may consider preventive CGRP therapy when dizziness/vertigo episodes are frequent or disabling, or when people have not responded well enough to standard preventive treatments. A diagnosis of vestibular migraine (rather than another vestibular disorder) is also important before starting migraine prevention.
What side effects should patients watch for?
Commonly discussed side effects of Aimovig in the context of migraine prevention include issues such as constipation and, more rarely, other tolerability concerns typical of CGRP-targeted monoclonal antibodies. Patients should also report any significant or persistent symptoms to their clinician promptly.
What risks or limitations should patients be aware of?
CGRP plays roles in the cardiovascular and gastrointestinal systems, so CGRP-blocking therapies may carry risks that require screening and follow-up. Also, because vestibular migraine has overlapping symptoms with inner ear and neurologic conditions, patients may need ongoing evaluation if symptoms do not improve as expected.
When should you seek help if vertigo doesn’t improve?
If dizziness/vertigo worsens, becomes continuous, or comes with new neurologic symptoms (such as weakness, numbness, trouble speaking, or severe new headache), it requires urgent medical evaluation to rule out causes other than vestibular migraine.
Sources
I don’t have the provided reference material needed to cite claims about Aimovig and vestibular migraine here. If you share the source text or links you want used, I can produce a fully cited answer tailored to those materials.